bioMérieux S.A.
BMXMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.32 | -1.55 | -1.06 | 0.50 |
| FCF Yield | 2.66% | 0.92% | 1.61% | 3.58% |
| EV / EBITDA | 13.50 | 13.79 | 13.64 | 14.15 |
| Quality | ||||
| ROIC | 9.04% | 7.48% | 10.50% | 16.13% |
| Gross Margin | 55.66% | 55.99% | 55.97% | 59.26% |
| Cash Conversion Ratio | 1.57 | 1.38 | 1.08 | 1.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.51% | 2.86% | 4.80% | 8.07% |
| Free Cash Flow Growth | 200.19% | -43.15% | -63.84% | 70.65% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.19 | -0.06 | -0.34 |
| Interest Coverage | 35.55 | 99.77 | 143.22 | 86.19 |
| Efficiency | ||||
| Inventory Turnover | 1.70 | 1.78 | 2.14 | 2.23 |
| Cash Conversion Cycle | 236.87 | 217.57 | 183.31 | 165.95 |